Page 154 - Haematologica Vol. 110 - January 2025

ARTICLE - R-GemOx+Atezo in R/R transformed DLBCL Table 2. Adverse events.
T. Othman et al.
Adverse events related to treatment with at least two grade ≥ 2 events, N (%)
Transformed follicular lymphoma Other transformed lymphomas
Grade 1-2 Grade 3-4 Grade 5 Grade 1-2 Grade 3-4 Grade 5
Cardiac arrest - 1 (7) - - - 1 (8)
White blood cell count decreased - 3 (21) - 2 (15) 1 (8) -
Lymphocyte count decreased - 4 (29) - 2 (15) 1 (8) -
Neutrophil count decreased 1 (7) 3 (21) - 2 (15) 2 (15) -
Fever 3 (21) - - 3 (31) 1 (8) -
Dyspnea - - - 1 (8) 1 (8) -
Acute kidney injury - 1 (7) - - 1 (8) -
Atrial fibrillation - - - - 1 (8) -
Hyperkalemia - - - - 1 (8) -
Hypernatremia 1 (7) - - - 1 (8) -
Respiratory failure - 1 (7) - - 1 (8) -
Platelet count decreased 3 (21) 3 (21) - 6 (46) 1 (8) -
Maculo-papular rash 2 (14) - - - 1 (8) -
Aspergillosis - 1 (7) - - - -
Multi-organ failure - 1 (7) - - - -
Sepsis - 1 (7) - - - -
Stevens-Johnson syndrome - 1 (7) - - - -
Hypertension 6 (43) 2 (14) - - 2 (15) -
Infusion related reaction 2 (14) - - 1 (8) 1 (8) -
Increased alanine transaminase 6 (43) - - 7 (54) 1 (8) -
Dizziness - - - - 1 (8) -
Febrile neutropenia - 1 (7) - - 1 (8) -
Anemia 3 (21) 1 (7) - 3 (31) - -
Hypokalemia 2 (14) 1 (7) - - - -
Hypocalcemia 1 (7) 1 (7) - - - -
Nausea/vomiting 5 (36) - - 7 (54) - -
Fatigue 7 (50) - - 8 (62) - -
Peripheral sensory neuropathy 2 (14) - - 3 (31) - -
response rates were 79% and 43%, respectively. In non-FL transformed lymphomas, the overall and complete re- sponse rates were 38% and 23%, respectively. There were three patients with transformed marginal zone lymphoma, of whom two achieved a complete response, while one pa- tient achieved a partial response. There were nine patients with RT; the overall and complete response rates were 22% and 11%, respectively. The median progression-free survival and overall survival of the total population were 3.7 and 7.7 months, respectively (Figure 3A). The median progression-free survival in patients with transformed FL or non-FL were 3.7 and 3.1 months, respectively (P=0.4) (Figure 3B), and the median overall survival for the two
groups were 22.5 and 7.3 months, respectively (P=0.4) (Figure 3C). Notably, one patient who received both an autologous HSCT and CAR T cells prior to enrollment had a partial response to R-GemOx+Atezo, while another patient who had been treated with mosunetuzumab and CAR T cells had progressive disease during treatment with R-GemOx+Atezo.
Discussion
R-GemOx+Atezo was tolerable and effective in R/R trans- formed DLBCL. The starting dose was the RP2D, and most
Haematologica | 110 January 2025
146